Navigation Links
Failure of Iclusig, Ariad’s Pharmaceutical Drug, No Surprise to CBCD
Date:10/20/2013

Rochester, NY (PRWEB) October 20, 2013

The failure of Ariad Pharmaceutical’s leukemia drug, Iclusig is no surprise to the CBCD. If top management at Ariad, and/or their investors, had turned to the CBCD, the Center would have told them that the chance of completing a successful clinical trial was almost zero.

What’s the argument? The productivity crisis in pharmaceutical R&D.

Iclusig was designed to target one specific molecule. However, like every drug, it impacts more than the specific molecule it was designed to target. When a drug impacts the ‘other’ molecules, it causes adverse reactions, or side effects. This was clearly the case in the development of Iclusig because in this case, some of the ‘other’ molecules were actually known.

As the author of an article published in February, 2013 in the formulary management journal P & T wrote, “The primary target (of Iclusig) is Bcr-Abl, an abnormal tyrosine kinase that is expressed in CML and Ph+ ALL (2).” If one carefully notes, however, the drug also “selectively blocks other tyrosine kinases, including FLT3, RET, KIT, and the members of the fibroblast growth factor receptor (FGFR) and platelet-derived growth factor (PDGFR) families (2).”

What kind of adverse reactions resulted from Iclusig’s impact on the ‘other’ molecules?

The answer is frightening. “Serious and fatal cases of arterial thrombosis (the formulation of a blood clot) and liver injury have occurred during treatment… cardiovascular, cerebrovascular, and peripheral vascular thrombosis, including fatal myocardial infarction (MI) (heart attack) and stroke have occurred in treated patients (2).”

In fact, because of these dangerous adverse reactions, “Ariad Pharmaceuticals Inc. abruptly terminated a pivotal clinical trial of its leukemia drug … a move that raised new safety questions and sent the company’s shares plunging more than 40 percent (1).”

Inclusig is
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NIH media availability: Protein linked to increased risk of heart failure and death in older adults
2. Heart Failure Society of America Annual Meeting To Feature Several Satellite Symposia
3. A new treatment for kidney disease-associated heart failure?
4. Blocking digestive enzymes may reverse shock, stop multiorgan failure
5. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
6. At Three Months Post Launch, Two-Thirds of Surveyed U.S. Rheumatologists Believe that Initiations of Pfizers Xeljanz in the Rheumatoid Arthritis Treatment Algorithm Will Occur Following at Least Two Biologic Failures
7. SynCardia Total Artificial Heart Bridges Mother of Four with Congenital Heart Defect & Biventricular Heart Failure to Transplant
8. The Prevention of Heart Failure
9. Center Of Reproductive Medicine Participates In The Thrive-IVF Research Study To Help Improve Pregnancy Success Rates And Outcomes In Women With A History Of Repeated In Vitro Fertilization (IVF) Failures
10. Houston Fertility Institute Participates In The Thrive-IVF Research Study To Help Improve Pregnancy Success Rates And Outcomes In Women With A History Of Repeated In Vitro Fertilization (IVF) Failures
11. Celladon Corporation Announces Publication of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... Diego, California (PRWEB) April 24, 2015 ... announced key milestones in its allogeneic stem-cell product ... Biopharma to properly reflect the corporate strategic direction. ... our allogeneic (donor) adipose stem cell development program ... completion of our cGMP manufacturing facility and hiring ...
(Date:4/24/2015)... SAN DIEGO , April 24, 2015  Pfenex ... in the development of biosimilar therapeutics including high value ... of its follow-on public offering of 6,000,000 shares of ... of $15.50 per share. Of the shares being offered, ... 3,390,000 shares are being offered by existing stockholders. Pfenex ...
(Date:4/24/2015)... April 24 , 2015 PAREXEL International ... services provider, today announced that Partnerships in Clinical Trials ... Management, the 2015 Clinical Innovator of the Year.  The ... team for the Company,s Perceptive MyTrials ® Data-Driven ... Thursday night during the 2015 Partnership Awards in ...
(Date:4/23/2015)... Athena San Diego, an organization that accelerates ... San Diego’s technology and life science sectors, will announce ... their Gala on April 30, 2015 from 5-9pm at ... http://athenasd.org/events/ , The Pinnacle Awards recognize individuals and ... of fostering networking, risk taking and diversity of thought, ...
Breaking Biology Technology:Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma 2Pfenex Inc. Announces Pricing Of Follow-on Offering 2PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 2PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 3PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 4PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 5Athena Pinnacle Awards to Honor Executives, Corporations and Educators Working to Promote Women Leaders 2
... and BioMed Central are announcing the launch ... today, a new online community for ... opportunities and industry news. (Logo: ... http://photos.prnewswire.com/prnh/20040907/CLTU006LOGO ) (Logo: http://photos.prnewswire.com/prnh/20100916/FL66006LOGO ...
... The PhD thesis by Carlos Echeverra Arrondo, Doctor in ... "On doped semiconductor quantum dots and magnetic nanowires", studied ... The interest aroused by nanoscience and nanotechnology spurred Dr ... their size is reduced to less than one hundred ...
... SIAL ) will be presenting at the UBS ... 12:30 PM ET in New York, NY. Interested parties may ... http://investor.sigmaaldrich.com/ .  Users can click the "Webcast" icon to ... Sigma-Aldrich is a leading Life Science and High Technology ...
Cached Biology Technology:BioSpace and BioMed Central Create Global Career Community 2Ph.D. study of behavior of semiconductor crystals of size less than 100 nanometers 2
(Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... of the "Global Iris Recognition Market 2015-2019" ... the Global Iris Recognition market to grow at a ... This report covers the present scenario and the ... the period 2015-2019. To calculate the market size, the ...
(Date:3/23/2015)... SoundView Technology Group issues a new research update ... Wocket smart wallet. SoundView was one of the selected user groups ... the Wocket in multiple scenarios and outlets. ... retailers, making both debit and credit card payments.  ... the company meets their plans in 2015, it would push ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... This press release is available in French . ... Cancer (IRIC) of the Universit de Montral have identified a ... the origin of several cancers. In an article published in ... recent discovery of a protein complex that controls the RAS/MAPK ...
... have discovered a disease mechanism that links hereditary amyotrophic lateral ... and points to a possible therapeutic target. The findings ... Nature Neuroscience . ALS is an adult-onset disease ... three to five years of diagnosis. Scott Brady, ...
... accumulating in municipal landfills, and reliance on imported oil ... new ultra-light biodegradable foam plastic material made from two ... The new substance could be used in furniture cushions, ... ACS, Biomacromolecules , a monthly journal. ...
Cached Biology News:Discovery of a mechanism that controls the expression of a protein involved in numerous cancers 2Link between 2 forms of ALS suggests drug target 2Link between 2 forms of ALS suggests drug target 3
...
... Nonanoyl-N-methylglucamide White solid. Water-soluble ... readily removed by dialysis. Useful reagent ... by HPLC. Absorbance (10%, H ... O. CMC 19 - 25 mM. ...
Anti Autotaxin /ENPP2 , - (Rabbit)...
... Tecans MiniPrep series of robotic workstations ... The MiniPrep is the ideal automation ... automation of routine laboratory procedures, improving throughput, ... based Gemini for MiniPrep software allows you ...
Biology Products: